One of DaVita’s (NYSE:DVA) corporate insiders, Michael David Staffieri, disclosed the purchase of DVA stock worth $5.24 million. It is important to highlight that Staffieri is the Chief Operating Officer at the DaVita Kidney Care Unit. DVA provides kidney care services, including dialysis and related treatments.
As per the SEC filing, the insider bought 100,000 shares of the company on February 21 at an average price of $52.41 per share.
Recent Events
It is worth highlighting that the insider purchased DVA’s shares following the release of the company’s better-than-expected Q4 results. During the reported quarter, the company’s revenues climbed by 8% year-over-year, and adjusted earnings increased by 174.6%.
Following the earnings release on February 13, DaVita received one Buy, three Holds, and one Sell rating from Wall Street analysts.
Is DVA a Good Stock?
Overall, on TipRanks, DaVita has a Hold consensus rating based on the analysts’ recommendations assigned in the past three months. The average DVA stock price target of $128.75 implies 2.8% upside potential from current levels. Shares of the company have gained over 51% in the past year.
Supporting the bull case, hedge funds have also increased their holdings of the stock. In the last quarter, hedge funds bought 777,400 shares of DVA. Overall, DaVita stock carries a “Perfect 10” Smart Score on TipRanks. These stocks have historically outperformed the S&P 500 Index (SPX) by a wide margin.
Discover the insider trading tool driving results for investors.
